A biosignature tool helps women avoid unnecessary radiotherapy after undergoing lumpectomy for ductal carcinoma in situ (DCIS) ― and also identifies women who need more intense treatment. The ...

Adjuvant radiation therapy (RT) for good-risk ductal carcinoma in situ (DCIS) reduced long-term ipsilateral breast recurrence (IBR) by more than 50% compared with observation, results of a large ...

Women with the non-invasive form of breast cancer known as ductal carcinoma in situ (DCIS) are more likely to have a disease recurrence after treatment consisting of lumpectomy alone if: their lesion ...

A polygenic risk score (PRS) may help identify women who are at a greater risk of developing a future breast cancer after treatment for in situ breast disease, a retrospective study suggests. The ...

A long-term follow up analysis of the NRG-RTOG 9804 randomized trial has shown that breast radiation following lumpectomy significantly reduces incidence of ipsilateral breast recurrence (IBR) for ...

LCCC 1025: A phase II study evaluating the mTOR inhibitor everolimus with trastuzumab and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. Background: Asignificant amount ...

Evaluation of a Multidisciplinary Immunotherapy Toxicity Monitoring Program for Patients Receiving Ipilimumab for Metastatic Melanoma Ductal carcinoma in situ (DCIS), a nonobligate precursor of breast ...

The hormone therapy tamoxifen can keep cancer from recurring in women with DCIS Tamoxifen following lumpectomy reduced risk of recurrence 44% to 51% Tamoxifen blocks estrogen receptors in cancer cells ...

Women with ductal carcinoma in situ—DCIS—who later develop invasive breast cancer in the same breast are at higher risk of dying from breast cancer than those who do not develop invasive disease, ...

Actress Danielle Fishel shared her breast cancer diagnosis this week, revealing on Monday's episode of her podcast, "Pod Meets World," that she is being treated for ductal carcinoma in situ (DCIS).